RPEBX | VEOIX | RPEBX / VEOIX | |
Total Expense Ratio | 1.21 | 0.73 | 166% |
Annual Report Gross Expense Ratio | 1.21 | 0.73 | 166% |
Fund Existence | 11 years | 3 years | - |
Gain YTD | 15.057 | 10.191 | 148% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 250 | 3000 | 8% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 159B | 85.1M | 186,839% |
Annual Yield % from dividends | 0.12 | 0.81 | 15% |
Returns for 1 year | 13.00 | 8.66 | 150% |
Returns for 3 years | 32.98 | N/A | - |
Returns for 5 years | 35.37 | N/A | - |
Returns for 10 years | 80.78 | N/A | - |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
PHPIX | 26.43 | 0.19 | +0.72% |
ProFunds Pharmaceuticals UltraSector Inv | |||
AEDCX | 32.59 | 0.08 | +0.25% |
Invesco EQV European Equity C | |||
QISCX | 28.29 | -0.04 | -0.14% |
Federated Hermes MDT Small Cap Core IS | |||
ASQAX | 16.34 | -0.06 | -0.37% |
American Century Small Company A | |||
VVORX | 22.06 | -0.14 | -0.63% |
Invesco Value Opportunities R |